Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization and a spin-off company of General Biol Co., Ltd, will provide cGMP-level oligonucleotide CRDMO services to the world using Cytiva’s first FlexFactory platform for oligo manufacturing.
